

## REVIEW ARTICLE

### PSYCHOSOCIAL CO-MORBIDITIES IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS): A SYSTEMATIC REVIEW<sup>1</sup>.

McKernan 0000-0001-9419-8502, L.C., Ph.D.,<sup>1-2</sup> Walsh, C.G., M.D., M.A.,<sup>1,3,4</sup> Reynolds, W.S., M.D., MPH,<sup>5</sup> Crofford, L.J., M.D.,<sup>3</sup> Dmochowski, R.R., M.D., MMHC<sup>5</sup>, & Williams, D.A., Ph.D.<sup>6</sup>

1. Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine
2. Department of Physical Medicine & Rehabilitation, Vanderbilt University School of Medicine
3. Department of Medicine, Vanderbilt University School of Medicine
4. Department of Biomedical Informatics, Vanderbilt University School of Medicine
5. Department of Urologic Surgery, Vanderbilt University School of Medicine
6. Department of Anesthesiology, University of Michigan

RUNNING HEAD: PSYCHOSOCIAL FACTORS IN IC/BPS

Word count in manuscript: 3547

Correspondence regarding this manuscript should be directed to:

Lindsey C. McKernan, Ph.D.

Assistant Clinical Professor, Departments of Psychiatry & Behavioral Sciences, Physical Medicine & Rehabilitation

Vanderbilt University Medical Center

Osher Center for Integrative Medicine

3401 West End Avenue, Suite 380

Nashville, TN 37203

Phone: (615) 875-9990 Email: [Lindsey.mckernan@vanderbilt.edu](mailto:Lindsey.mckernan@vanderbilt.edu)

#### Acknowledgements

We gratefully acknowledge Philip Walker, MA, Medical Librarian, Vanderbilt University Medical Center, for his invaluable assistance with the search strategy for this manuscript.

This manuscript was prepared with support from the Vanderbilt Patient Centered Outcomes Research Education and Training Initiative and the Agency for Healthcare Research and Quality (AHRQ 6K12HS022990-03).

### PSYCHOSOCIAL CO-MORBIDITIES IN INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS): A SYSTEMATIC REVIEW.

<sup>1</sup> This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:[10.1002/nau.23421](https://doi.org/10.1002/nau.23421)

McKernan, L.C., Ph.D.,<sup>1-2</sup> Walsh, C.G., M.D., M.A.,<sup>1,3,4</sup> Reynolds, W.S., M.D., MPH,<sup>5</sup>  
Crofford, L.J., M.D.,<sup>3</sup> Dmochowski, R.R., M.D., MMHC<sup>5</sup>, & Williams, D.A., Ph.D.<sup>6</sup>

1. Department of Psychiatry and Behavioral Sciences, Vanderbilt University School of Medicine
2. Department of Physical Medicine & Rehabilitation, Vanderbilt University School of Medicine
3. Department of Medicine, Vanderbilt University School of Medicine
4. Department of Biomedical Informatics, Vanderbilt University School of Medicine
5. Department of Urologic Surgery, Vanderbilt University School of Medicine
6. Department of Anesthesiology, University of Michigan

RUNNING HEAD: PSYCHOSOCIAL FACTORS IN IC/BPS

Word count in manuscript: 3547

Correspondence regarding this manuscript should be directed to:

Lindsey C. McKernan, Ph.D.

Assistant Clinical Professor, Departments of Psychiatry & Behavioral Sciences, Physical  
Medicine & Rehabilitation

Vanderbilt University Medical Center

Osher Center for Integrative Medicine

3401 West End Avenue, Suite 380

Nashville, TN 37203

Phone: (615) 875-9990 Email: [Lindsey.mckernan@vanderbilt.edu](mailto:Lindsey.mckernan@vanderbilt.edu)

#### Acknowledgements

We gratefully acknowledge Philip Walker, MA, Medical Librarian, Vanderbilt University Medical Center, for his invaluable assistance with the search strategy for this manuscript.

This manuscript was prepared with support from the Vanderbilt Patient Centered Outcomes Research Education and Training Initiative and the Agency for Healthcare Research and Quality (AHRQ 6K12HS022990-03).

## Abstract

**Aims:** Psychosocial factors amplify symptoms of Interstitial Cystitis (IC/BPS). While psychosocial self-management is efficacious in other pain conditions, its impact on an IC/BPS population has rarely been studied. The objective of this review is to learn the prevalence and impact of psychosocial factors on IC/BPS, assess baseline psychosocial characteristics, and offer recommendations for assessment and treatment. **Method:** Following PRISMA guidelines, primary information sources were PubMed including MEDLINE, Embase, CINAHL, and GoogleScholar. Inclusion criteria included: 1) a clearly defined cohort with IC/BPS or with Chronic Pelvic Pain Syndrome provided the IC/BPS cohort was delineated with quantitative results from the main cohort; 2) all genders and regions; 3) studies written in English from 1995- April 14, 2017; 4) quantitative report of psychosocial factors as outcome measures or at minimum as baseline characteristics.

**Results:** 34 of an initial 642 articles were reviewed. Quantitative analyses demonstrate the magnitude of psychosocial difficulties in IC/BPS, which are worse than average on *all measures*, and fall into areas of *clinical concern* for 7 out of 10 measures. Meta-analyses shows mean Mental Component Score of the Short-Form 12 Health Survey (MCS) of 40.80 (SD 6.25, N=2912), where <36 is consistent with severe psychological impairment. Averaged across studies, the population scored in the range seen in clinical depression (CES-D 19.89, SD 13.12, N = 564) and generalized anxiety disorder (HADS-A 8.15, SD 4.85, N = 465).

**Conclusion:** The psychological impact of IC/BPS is pervasive and severe. Existing evidence of treatment is lacking and suggests self-management intervention may be helpful.

**Keywords:** Interstitial Cystitis, Bladder Pain Syndrome, IC/BPS, Psychosocial, Depression, Anxiety, Trauma, Systematic Review

Psychosocial Co-Morbidities in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): A Systematic Review.

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a debilitating, incurable, and costly pain condition affecting approximately 3-8 million individuals in the United States<sup>1</sup>. The economic burden of the condition is substantial, costing the healthcare system upwards of \$750 million a year<sup>2</sup>. Pain is the hallmark symptom of IC/BPS –

which occurs in the region of the pelvis, urogenital floor, or external genitalia. In addition, most patients experience urgency, pressure/discomfort, and/or urinary frequency<sup>3</sup>. There is a limited understanding of IC/BPS pathophysiology and most treatments target symptom control. Biomedically-based treatments currently lack effectiveness<sup>4</sup>. Between 1992-2001 the rates of physician office visits for IC/BPS tripled and outpatient hospital visits doubled<sup>2</sup>.

Evidence suggests psychosocial factors, such as co-morbid anxiety, depression, quality of life, and trauma-related symptoms accompany and intensify the illness<sup>5,6</sup>. Unaddressed psychosocial elements of chronic pain can shape patient perceptions and behavior, often leading to increased chronicity of symptoms and are associated with poorer functioning, adjustment, prognosis, and response to treatment<sup>6-10</sup>. These findings suggest not only a strong association, but also that psychosocial symptoms and bladder-specific symptoms reinforce one another.

Although there is a recognized need for psychosocial intervention as a first-line treatment for IC/BPS per national guidelines<sup>4</sup>, these interventions are difficult to implement in actual practice and as such they are underutilized. It is also unknown if the recommended therapies suggested in these guidelines sufficiently meet patient needs or whether patients with IC/BPS require a broader pain self-management approach as is used with other forms of chronic pain<sup>11</sup>. As there is paucity of randomized controlled trials evaluating how these interventions work and for whom, little is known about the impact of treating psychosocial factors on outcome.

While much is being learned about IC/BPS through Federally-sponsored research (e.g., Multidisciplinary Approach to the study of Pelvic Pain/MAPP<sup>12</sup>), including

widespread psychosocial difficulties in IC/BPS<sup>9</sup>, there has yet to be a comprehensive review of the existing evidence examining psychosocial factors and IC/BPS. The objective of this review is to learn the prevalence and impact of psychosocial factors on IC/BPS, and assess baseline psychosocial characteristics. This is the first systematic review to our knowledge on the data available on the prevalence and impact of IC/BPS on psychosocial variables such as co-morbid mental health conditions, psychological states, and quality of life. Having this information will help future researchers 1) capture relevant treatment outcomes, 2) provide guidance on assessment domains, and 3) increase knowledge to inform treatment approaches. This systematic review synthesizes the existing evidence of psychosocial factors associated with IC/BPS and, when possible, provides additional normative data as a tool for comparison. We then offer recommendations for assessment and treatment.

## **Methods**

### *Search Strategy*

We performed a systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Framework<sup>13</sup>. In consultation with a medical librarian, we established a review strategy to identify studies that differentiated cohorts with Interstitial Cystitis as either the primary study population or as a sub-cohort of analysis. The primary information sources were PubMed including MEDLINE, Embase, CINAHL, and Google Scholar.

Study inclusion criteria included: 1) a clearly defined cohort with Interstitial Cystitis or with Chronic Pelvic Pain Syndrome provided the Interstitial Cystitis cohort was delineated with quantitative results from the main cohort; 2) all genders; 3) studies

written in English from 1995- April 14, 2017; 4) any study region; 5) quantitative report of psychosocial factors as outcome measures or at minimum as baseline characteristics. We focused on psychosocial attributes including trauma, anxiety, depression, panic traits or quality of life measures. The use of validated instruments or self-report measures was not required but was noted when present in study results.

Search phrases were defined in MeSH and in Google Scholar and are shown below in Table 1.

#### [TABLE 1]

Identified studies were screened for duplicates and subsequently underwent title and abstract review according to the criteria above. The resultant corpus of studies that fit our inclusion criteria were then reviewed in full-text. Data items were collected for each study: authorship, title, journal, year of publication, study design, study inclusion criteria, sample size, psychosocial measure(s) or prevalence, targeted outcome(s). One reviewer evaluated each study in detail. In the 5 cases where there was uncertainty regarding eligibility of the study for inclusion, additional reviewers (CW, WSR) were consulted.

#### *Results Synthesis*

We evaluated eligible publications (total N = 34) for both qualitative and quantitative data. The former incorporated a review of study design, methodology, and presence of an intervention designed to impact psychosocial measures or whether such measures were recorded as part of baseline characterization. Study limitations were also

considered and recorded. Quantitative analyses included psychosocial measures and variances/standard deviations if reported.

For studies with quantified psychosocial measures (N = 17), meta-analysis was performed with pooled statistics grouped by measure, e.g. SF-36, and by targeted outcome, e.g. trauma or abuse, if reported. We assumed equal population variances across studies given our inclusion criteria delineating the population with IC and therefore applied pooled variances with Bessel's correction to study results. We then compared pooled statistics against guidelines for clinical interpretation provided for each measure (see Table 3). Variables were calculated if more than one study used a given measure. Bias assessment was informed by the Cochrane Risk of Bias Tool though we note that the primarily observational nature of most research in this area coupled with relatively small sample sizes indicated common sources of bias and precluded rigorous application of this tool or others like Downs and Black<sup>14</sup>. These biases will be reviewed in aggregate (see Results).

[FIGURE 1]

## **Results**

Using the inclusion criteria described above, the final number of reviewed articles was 34 out of 642 search results (see Figure 1). We have consolidated the details and primary findings of each study in Table 2. The review of psychosocial factors in IC/BPS is broken down into the following domains: depression, anxiety, stress/coping, trauma, quality of life, and demographic factors. We then detail findings of pooled statistics in available studies and place them in the context of population norms. Due to the limited

evidence available on treatment studies, we do not qualitatively review them. Instead, we discuss the implications of their primary findings in our discussion.

## [TABLE 2]

### 1. Depression

The impact of depression on IC/BPS was assessed in 16 of 34 studies. Study measures primarily involved self-reported symptoms of depression, with one study evaluating clinical diagnoses by chart review. Depression rates were elevated in all 16 studies, with prevalence rates ranging from 16-70%, fluctuating largely based on study type, sample size, and assessment method. Women with IC/BPS are between 2.4-6.6 times more likely to be diagnosed with depression than controls<sup>15-17</sup>, and 4 times more likely to use psychotropic medications. Depression is consistently associated with worsened symptom presentation, particularly in early stages of illness<sup>16,17</sup>. Patients who are depressed are less likely to work<sup>6</sup>, and are more likely to present with polysymptomatic complaints<sup>9</sup>. Helplessness, a symptom of depression, was associated with worsened mental functioning<sup>18</sup>. In a recent study, 23% of patients acknowledged experiencing suicidal ideation, which was associated with greater pain and worsened mental health functioning<sup>19</sup>.

### 2. Anxiety and Panic

Anxiety was assessed in 10 of 34 studies, with 8 assessing symptoms through self-report measures, 2 evaluating clinical diagnoses given during medical record review, and 1 structured and validated clinical interview assessing for the presence of an anxiety disorder. Prevalence rates of anxiety symptoms in IC/BPS ranged from 14-52%. Regarding diagnosed conditions, individuals are 4.37 times more likely to have a pre-



existing anxiety disorder prior to developing IC/BPS<sup>20</sup> and are 2.4 times more likely to develop an anxiety disorder following IC/BPS diagnosis<sup>16</sup>. Similarly, in another study, panic disorder was diagnosed in 26.9% of cases, indicating that women with IC/BPS are 4.1 times more likely than those with other urological disease to develop panic disorder in their lifetime – and to have first degree relatives that are twice as likely to have panic disorder<sup>21</sup>. Patients with anxiety also show increased urinary symptom severity and lower self-esteem<sup>22</sup>.

### 3. Stress and Coping

Nine studies measured stress and coping by assessing catastrophic thought processes<sup>18,19,23-26</sup>, perceived stress<sup>9,23,24</sup>, and self-efficacy<sup>27,28</sup>. Catastrophizing, or an internal exaggeration of events, rumination, or sense of helplessness in response to pain, is consistently related to worsened outcomes in mental and physical functioning<sup>18,19,25</sup>. In addition, catastrophizing increases vulnerability to suicidal ideation<sup>19</sup>. Both genders show heightened generalized stress levels, often in spite of the severity of symptoms<sup>23,26</sup>. Those with greater self-efficacy experienced less pain and depression<sup>28</sup>.

### 4. Trauma Sequelae

Six studies measured abuse prevalence via validated self-report<sup>5,9,24,29</sup>, non-validated questionnaires<sup>30,31</sup>, and clinical interview of trauma exposure<sup>30</sup>. One study measured dissociative tendencies<sup>29</sup>. Overall abuse prevalence rates range from 25-49%. Trauma and abuse prevalence rates range significantly by method of reporting and abuse type. For example, between 21-40% of patients endorsed exposure to traumatic events as a child on self-report questionnaires. When asked directly via clinical interview, this number increased significantly in one study<sup>30</sup>, while decreasing in another study when

asked directly “were you abused as an adult/child,” without a definition of ‘abuse’<sup>5</sup>.

Abuse in childhood and adulthood is more common in female patients<sup>9</sup>. The presence of sexual abuse has been associated with altered symptom presentation, where patients experiencing greater sensory pain<sup>24,31</sup>, less daytime frequency and nocturia, larger voided volumes,<sup>31</sup> and worsened sexual functioning<sup>31,32</sup> – although one study notes this relationship is at most very modest<sup>24</sup>.

#### 5. Quality of Life Factors

Twenty-one studies included a measure of quality of life. This most often included a broad measure on different life areas, and in some cases more specific aspects of daily life including insomnia, social support, self-esteem, and sexual functioning. Overall physical and mental quality of life is significantly impacted across the population. Quality of life is often worsened with increased symptom severity and co-occurring psychological difficulties<sup>6,23</sup>. Self-esteem and social functioning are both significantly impacted by IC/BPS<sup>22</sup> when compared to controls. Impaired sexual functioning is a common occurrence in the population; however, there was evidence of hesitancy in reporting this to providers or on questionnaires.

#### 6. Demographic factors

Age is a significant factor when considering the psychosocial impact of symptoms. Studies found that younger individuals have increased risk of developing psychological co-morbidities and insomnia following IC/BPS diagnosis<sup>16</sup>, have significantly diminished quality of life<sup>33</sup>, and are at higher risk for depression in the earlier stages of illness<sup>17</sup>. This was true of both genders. These individuals are also more likely to utilize healthcare services for depression and anxiety<sup>16</sup>. Gender was also shown to impact

symptom presentation, although these results are mixed. Women are more likely to present with polysymptomatic complaints<sup>9,23,34</sup>. The examination of abuse prevalence has occurred predominately in females. In the most comprehensive psychological study to date, comparing gender, Naliboff and colleagues (2015) found that women are more likely to report early life and adult trauma exposure, greater helplessness, and poorer functionality than men – irrespective of symptom severity or age. Although there is less available information on men with IC/BPS, a large population-based study showed that younger men were at higher risk of developing depression following IC/BPS diagnosis<sup>16</sup>. Other studies showed no gender differences in mental health presentation<sup>15</sup>.

#### 7. Quantitative Analyses

Pooled population means and standard deviations for psychosocial variables are presented in Table 3, along with clinical cutoff and suggested interpretations for each measure. Results clearly demonstrate the magnitude of psychosocial difficulties in IC/BPS, which are worse than average on *all measures*, and fall into areas of *clinical concern* for 7 out of 10 measures when following guidelines for clinical interpretation (see Table 3). The population's baseline psychological functioning is considered "depressed" according to two commonly used measures to assess depression. For example, of 564 subjects provided with the Center for Epidemiological Studies of Depression, or CES-D<sup>35</sup>, the mean response was 19.89. The clinical "cutoff" for this measure indicating extremely likely depression is 16<sup>35</sup>, or 19 in chronic pain patients.<sup>36</sup> Patients are much more likely to have an anxiety disorder and have stress levels of clinical concern. Of 465 subjects administered the Hospital Anxiety and Depression Scale (HADS-A), the mean response was 8.15. On this measure, a score greater than

“8” indicates a 78% likelihood of having Generalized Anxiety Disorder<sup>37</sup>. There is significant impairment in quality of life in both mental (MCS = 40.80 (6.25), N = 2912) and physical (PCS = 42.37 (6.67), N = 2912) functioning. For mental functioning, this is well below population averages, and approaching “severe psychological impairment.”<sup>38,39</sup> Quality of life measures indicate that at baseline women are at significant risk of sexual dysfunction (FSFI = 16.37, SD 8.12, N = 926). Although Catastrophizing scores were elevated compared to population norms, the average scores of the two scales did not fall in the range of clinical concern.

[TABLE 3] [TABLE 4]

*Risk of bias in reporting and study limitations:*

Evaluating the psychosocial aspects of IC/BPS remains a relatively new area of study. There are limitations to note about the current literature. The most common method of evaluation was via self-report measures. These assessments cannot make definitive psychological diagnoses and are generally used as screening tools. Assessments given also lacked in consistency, making a collective analysis of studies difficult. Some of these measures did not adequately capture the outcomes assessed. For example, two used the Medical Outcomes Survey<sup>39</sup> sexual functioning scale, which does not measure sexual pain – a common experience impacting sexual functioning in IC/BPS. Some assessments suffered from a low response rate, (e.g.. Female Sexual Functioning Index<sup>40</sup> in mailed questionnaires from studies), and used measures lacking in validity<sup>30,41</sup>. There are concerns of under-reporting with trauma, abuse, and sexual dysfunction due to discomfort with disclosure<sup>5,30</sup>. Roughly half of the studies lacked control groups. Sample sizes of clinical cohort studies were low in many of the studies reported. Data

collected were often in convenience samples, with primarily white women in tertiary care centers. Many assessments were observational at one time point. The majority of studies cited did not follow patients over time. Even the treatment studies listed had limited, short-term follow-up. The three RCTs reported were not adequately powered to reliably assess for treatment effects.

## **Discussion**

This study is the first to provide a comprehensive review of the existing evidence evaluating psychosocial factors in IC/BPS. We reviewed 34 studies to provide a synthesis of the literature and guidance for future studies.

The psychological and social impact of IC/BPS is pervasive. There is significantly increased likelihood of an anxiety or depressive disorder both preceding and following IC/BPS diagnosis. Symptoms of anxiety, depression, and generalized stress, and increased suicidal ideation are paramount. Individuals are more likely to engage in catastrophic thought processes, which globally worsens functioning. IC/BPS has a detrimental impact on quality of life, self-esteem and social functioning. Pooled statistics indicate that at baseline, mean scores on measures of anxiety, depression, and stress fall in areas of clinical concern as defined by their clinical interpretation guidelines (see Table 3).

### *Implications for Assessment*

In future studies we strongly recommend using validated measures to reliably capture psychosocial symptoms and diagnoses. When possible, evaluating psychological

disorders associated with IC/BPS is best accomplished through a validated clinical interview. This was performed in one of the studies reviewed<sup>21</sup>, and will help provide the most accurate and reliable assessment of conditions beyond screening measures. In Table 3, we provide an overview of assessments most commonly used for psychosocial variables in IC/BPS, with guidelines for clinical interpretation. It is our hope that this can serve as a guide to future researchers, while also providing benchmarks for clinicians and further study. Table 4 outlines recommendations for assessment of pain in urologic disease provided by Williams (2013). In addition to pain symptoms and medical co-morbidity, a comprehensive assessment includes affective vulnerability, patient beliefs and attitudes, and a patient's environment/social relationships. Many of the recommended assessments in Table 4 were not available for meta-analysis (used in <2 studies reviewed) or had not been used. In the future we recommend expanding on current research by using this reference as a guideline to structure a comprehensive assessment in clinical studies of IC/BPS.

*Trauma exposure:* While a relationship between trauma exposure and IC/BPS has been established in studies to date, the nature and impact of the association has yet to be fully elucidated. Future studies are in need of comprehensively assessing trauma across the lifespan, and simultaneously assessing active symptoms of post-traumatic stress disorder (PTSD). Of the studies reviewed, no studies evaluated active symptoms of PTSD. Post-traumatic stress is known to exacerbate and maintain pain symptoms, and untreated PTSD has the potential to significantly impact the treatment course.

In one study, 29 of 30 women with childhood sexual abuse did not report this to their doctor<sup>5</sup>. Abuse exposure should be routinely assessed in clinical settings. As this is a difficult topic to broach with patients, a more appropriate screening measure may be to *evaluate symptoms associated with trauma exposure* – as opposed to direct questioning. This is employed in primary care settings with measures such as the 4-item Primary Care – PTSD Screen (PC-PTSD<sup>42</sup>) and may reduce discomfort with direct disclosure.

### *Treatment Implications*

The demographic findings detailed above suggest that the early stages of illness are a particularly vulnerable period. Early access to psychological intervention may interrupt the development of these conditions, which could have important implications for illness prognosis. Gender differences may also impact symptom presentation and treatment approach. A recent review examining Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) found elevated prevalence rates of depression and anxiety disorder, but not panic disorder among patients<sup>43</sup>. This suggests that treatment approaches may have different targets of intervention depending on gender – however, further studies are needed to clarify these differences.

From evidence provided in this review, it is clear that untreated psychosocial factors worsen symptom presentation and prognosis. Untreated psychosocial comorbidities may significantly impact the treatment process as well. Depressed patients are known as less likely to follow treatment recommendations. Helplessness and Catastrophizing influence patient behavior, lack of agency, and over-reliance on providers. Patients who experience anxiety may avoid procedures. For a patient with a

sexual abuse history and/or PTSD, routine exams, urologic diagnostic procedures, and/or manual physical therapy have the potential to be re-traumatizing<sup>44</sup>.

Accompanying recommendations from the AUA regarding first-line interventions for IC/BPS, the most recent National Pain Strategy (2015) highlights the importance of taking an integrated, multimodal approach to managing pain in order to address the biopsychosocial factors influencing pain. The inclusion of a mental health provider into a multimodal treatment plan for IC/BPS has the potential to improve symptoms, quality of life, and treatment adherence.

#### *Findings of self-management interventions*

Of the three investigations to date, there are initial indications that self-management strategies have the ability to significantly improve symptoms and wellbeing in IC/BPS. Each study utilized a different approach – guided imagery/self-hypnosis<sup>27</sup>, mindfulness<sup>46</sup>, and online health education<sup>47</sup>. Although these investigations were all pilot studies and had limited follow-up, the findings are promising. Those treated reported significant reductions in pain and urinary urgency<sup>46,47</sup>, had greater perceived control of symptoms<sup>46</sup>, and better healthcare outcomes than controls<sup>47</sup>. The impact of these interventions on psychological states and co-morbidity has yet to be assessed.

A large proportion of the studies in this review urge the integration of psychological assessment and management into care plans for IC/BPS. Psychosocial self-management interventions could benefit patients through bolstering self-efficacy and increasing social support - which are known to buffer the impact of symptoms<sup>28,48</sup>, by improving treatment adherence<sup>33</sup>, and by reducing the impact of psychological co-



morbidities that intensify the illness. These interventions may also be preferable as patients are often not responsive to psychotropic medications<sup>15</sup>. As psychological distress occurs across patient phenotype<sup>9,26</sup>, and many patients with only moderate symptoms have significant psychological burden<sup>9,49</sup>, patients at all stages of the illness could benefit. A recent survey conducted in collaboration with the Interstitial Cystitis Association (N = 1,982; <sup>50</sup>) revealed that there is significant interest in and perceived benefits of employing self-management strategies such as stress reduction, sleep hygiene, relaxation, and meditation as well as engaging in active coping strategies to alleviate symptoms. This is a new area of clinical investigation with significant potential which patients are open to. Future well-controlled studies with larger sample sizes, comprehensive assessment, and long-term follow up are indicated.

#### *Strengths and limitations of review*

This study accumulates previous literature and presents the best available evidence for the associations between and impact of psychological co-morbidities and IC/BPS. A strength of the current study is its comprehensive and reproducible search strategy. A limitation of this review is our inability to perform a true meta-analysis due to the limited literature available. Future studies are needed with longer-term follow-up and larger sample sizes. In addition comprehensive psychosocial assessment, including an assessment of PTSD symptoms is recommended. We believe that continued self-management intervention research is necessary based on the preliminary information available. We suspect that given the emerging evidence of a patient phenotype, interventions will likely need to be tailored to patient presentation.

The study of IC/BPS has largely been limited to females. As research is leaning towards conceptualizing IC/BPS and CP/CPPS as a unified condition (“UCPPS”<sup>12</sup>), examining the literature in both conditions may provide more information regarding gender differences and treatment individualization.

### Conclusion

The psychological impact of IC/BPS is pervasive and severe. Existing evidence of treatment is lacking and suggests self-management intervention may be helpful.

### References

1. Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. *J Urol.* 2011;186(2):540-544.
2. Payne CK, Joyce GF, Wise M, Clemens JQ. Interstitial cystitis and painful bladder syndrome. *J Urol.* 2007;177(6):2042-2049.
3. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *J Urol.* 2015;193(5):1545-1553.
4. Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *Journal of Urology.* 2011;185(6):2162-2170.
5. Goldstein H, Safaeian P, Garrod K, Finamore P, Kellogg-Spadt S, Whitmore K. Depression, abuse and its relationship to interstitial cystitis. *Int Urogynecol J.* 2008;19(12):1683.
6. Watkins KE, Eberhart N, Hilton L, et al. Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. *General hospital psychiatry.* 2011;33(2):143-149.
7. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. *Pain.* 2000;85(3):317-332.
8. Watkins KE, Eberhart N, Hilton L, et al. Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. *General hospital psychiatry.* 2011;33(2):143-149.
9. Naliboff BD, Stephens AJ, Afari N, et al. Widespread Psychosocial Difficulties in Men and Women With Urologic Chronic Pelvic Pain Syndromes: Case-control Findings

- From the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network. *Urology*. 2015;85(6):1319-1327.
10. Koh JS, Ko HJ, Wang SM, et al. The impact of depression and somatic symptoms on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: a preliminary study in a naturalistic treatment setting. *International journal of clinical practice*. 2014;68(4):478-485.
  11. Hassett AL, Williams DA. Non-pharmacological treatment of chronic widespread musculoskeletal pain. *Best practice & research Clinical rheumatology*. 2011;25(2):299-309.
  12. Clemens JQ, Mullins C, Kusek JW, et al. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. *BMC urology*. 2014;14(1):57.
  13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009;6(7):e1000097.
  14. Downs SJ, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *Journal of Epidemiology and Community Health*. 1998;52:377-384.
  15. Clemens JQ, Brown SO, Calhoun EA. Mental Health Diagnoses In Patients with Interstitial Cystitis/ Painful Bladder Syndrome and Chronic Prostatitis/ Chronic Pelvic Pain Syndrome: A Case/Control Study. *The Journal of urology*. 2008;180(4):1378-1382.
  16. Chuang Y-C, Weng S-F, Hsu Y-W, Huang CL-C, Wu M-P. Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. *International urology and nephrology*. 2015;47(2):275-281.
  17. Novi JM, Jeronis S, Srinivas S, Srinivasan R, Morgan MA, Arya LA. Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. *J Urol*. 2005;174(3):937-940.
  18. Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A. Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. *Urology*. 2009;73(5):987-992.
  19. Tripp DA, Nickel JC, Krsmanovic A, et al. Depression and catastrophizing predict suicidal ideation in tertiary care patients with interstitial cystitis/bladder pain syndrome. *Canadian Urological Association Journal*. 2016;10(11-12):383-388.
  20. Chung KH, Liu SP, Lin HC, Chung SD. Bladder pain syndrome/interstitial cystitis is associated with anxiety disorder. *Neurourology and urodynamics*. 2014;33(1):101-105.
  21. Weissman MM, Gross R, Fyer A, et al. Interstitial cystitis and panic disorder: a potential genetic syndrome. *Archives of general psychiatry*. 2004;61(3):273-279.
  22. Rapariz-Gonzalez M, Castro-Diaz D, Mejia-Rendon D. Evaluation of the impact of the urinary symptoms on quality of life of patients with painful bladder syndrome/chronic pelvic pain and radiation cystitis: EURCIS study. *Actas urologicas espanolas*. 2014;38(4):224-231.

23. Lai HH, Krieger JN, Pontari MA, Buchwald D, Hou X, Landis JR. Painful bladder filling and painful urgency are distinct characteristics in men and women with urological chronic pelvic pain syndromes: A MAPP research network study. *Journal of Urology*. 2015;194(6):1634-1641.
24. Nickel JC, Tripp DA, Pontari M, et al. Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. *Canadian Urological Association journal = Journal de l'Association des urologues du Canada*. 2011;5(6):410-415.
25. Rothrock NE, Lutgendorf SK, Kreder KJ. Coping strategies in patients with interstitial cystitis: Relationships with quality of life and depression. *Journal of Urology*. 2003;169(1):233-236.
26. Tripp DA, Nickel JC, Wong J, et al. Mapping of Pain Phenotypes in Female Patients with Bladder Pain Syndrome/Interstitial Cystitis and Controls. *European Urology*. 2012;62(6):1188-1194.
27. Carrico DJ, Peters KM, Diokno AC. Guided imagery for women with Interstitial Cystitis: Results of a prospective, randomized controlled pilot study. *The Journal of Alternative and Complementary Medicine*. 2008;14(1):53-60.
28. Rabin C, O'Leary A, Neighbors C, Whitmore K. Pain and depression experienced by women with interstitial cystitis. *Women & health*. 2001;31(4):67-81.
29. Chiu C-D, Lee M-H, Chen W-C, Ho HL, Wu H-C. Childhood trauma perpetrated by close others, psychiatric dysfunction, and urological symptoms in patients with interstitial cystitis/bladder pain syndrome. *Journal of psychosomatic research*. 2017;93:90-95.
30. Peters KM, Kalinowski SE, Carrico DJ, Ibrahim IA, Diokno AC. Fact or fiction--is abuse prevalent in patients with interstitial cystitis? Results from a community survey and clinic population. *The Journal of urology*. 2007;178(3 Pt 1):891-895; discussion 895.
31. Seth A, Teichman JM. Differences in the clinical presentation of interstitial cystitis/painful bladder syndrome in patients with or without sexual abuse history. *The Journal of urology*. 2008;180(5):2029-2033.
32. Nickel JC, O'Leary MP, Lepor H, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. *J Urol*. 2011;186(1):125-131.
33. Nickel JC, Payne CK, Forrest J, Parsons CL, Wan GJ, Xiao X. The relationship among symptoms, sleep disturbances and quality of life in patients with interstitial cystitis. *J Urol*. 2009;181(6):2555-2561.
34. Lai HH, North CS, Andriole GL, et al. Urological Symptoms in a Subset of Patients with Urological Chronic Pelvic Pain Syndrome and a Polysymptomatic, Polysyndromic Pattern of Presentation. *Journal of Urology*. 2014;191(6):1802-1807.
35. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Applied psychological measurement*. 1977;1(3):385-401.
36. Turk DC, Okifuji A. Detecting depression in chronic pain patients: adequacy of self-reports. *Behaviour research and therapy*. 1994;32(1):9-16.
37. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. *Journal of psychosomatic research*. 2002;52(2):69-77.

38. Gill SC, Butterworth P, Rodgers B, Mackinnon A. Validity of the mental health component scale of the 12-item Short-Form Health Survey (MCS-12) as measure of common mental disorders in the general population. *Psychiatry Research*. 2007;152(1):63-71.
39. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Medical care*. 1996;34(3):220-233.
40. Rosen CB, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D'Agostino, R. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *Journal of Sex & Marital Therapy*. 2000;26(2):191-208.
41. Sairanen J, Leppilahti M, Tammela TL, et al. Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it. *Scandinavian journal of urology and nephrology*. 2009;43(3):212-219.
42. Cameron RP, Gusman D. The primary care PTSD screen (PC-PTSD): development and operating characteristics. *Primary Care Psychiatry*. 2003;9(1):9-14.
43. Riegel B, Bruenahl CA, Ahyai S, Bingel U, Fisch M, Lowe B. Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men - A systematic review. *Journal of Psychosomatic Research*. 2014;77(5):333-350.
44. McKernan LC, Carr ER, Nash M. An integrative trauma-based approach toward chronic pain: Specific applications to Interstitial Cystitis/Bladder Pain Syndrome. *Journal of Psychotherapy Integration* 2016;26(1):1-15.
45. Department of Health and Human Services. National Pain Strategy: A Comprehensive Population Health Strategy for Pain. 2015.
46. Kanter G, Komesu YM, Qaedan F, et al. Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: A randomized controlled trial. *Int Urogynecol J*. 2016;27(11):1705-1711.
47. Lee MH, Wu HC, Lin JY, Tan TH, Chan PC, Chen YF. Development and evaluation of an E-health system to care for patients with bladder pain syndrome/interstitial cystitis. *International journal of urology : official journal of the Japanese Urological Association*. 2014;21 Suppl 1:62-68.
48. El Khoudary SR, Talbott EO, Bromberger JT, Chang CCH, Songer TJ, Davis EL. Severity interstitial cystitis symptoms and quality of life in female patients. *Journal of Women's Health*. 2009;18(9):1361-1368.
49. Konkle KS, Berry SH, Elliott MN, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. *J Urol*. 2012;187(2):508-512.
50. O'Hare PG, 3rd, Hoffmann AR, Allen P, Gordon B, Salin L, Whitmore K. Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies. *Int Urogynecol J*. 2013;24(6):977-982.
51. Fazio RL, Wunderlich T, Wilson N, Akeson S. MMPI-2-RF characteristics of individuals with interstitial cystitis. *Journal of Psychosomatic Research*. 2014;77(5):359-362.

52. Kim J-I, Heitkemper MM. Interstitial Cystitis/Painful Bladder Syndrome: Prevalence Estimates, Quality of Life and Depression among Older Adult Korean Women. *Korean Journal of Women Health Nursing*. 2009;15(4):381-386.
53. Nickel JC, Parsons CL, Forrest J, et al. Improvement in sexual functioning in patients with interstitial cystitis/painful bladder syndrome. *J Sex Med*. 2008;5(2):394-399.
54. Zaslau S, Riggs DR, Perlmutter AE, Jackson BJ, Osborne J, Kandzari SJ. Sexual dysfunction in patients with painful bladder syndrome is age related and progressive. *The Canadian journal of urology*. 2008;15(4):4158-4162.
55. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. *San Antonio*. 1996;78(2):490-498.
56. Cohen S, Kamarck T, Mermelstein R. Perceived stress scale. *Measuring stress: A guide for health and social scientists*. 1994.
57. Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. *Pain*. 1983;17(1):33-44.
58. Sullivan MJ, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. *Psychological assessment*. 1995;7(4):524.
59. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. *Journal of sex & marital therapy*. 2005;31(1):1-20.
60. Williams DA. The Importance of Psychological Assessment in Chronic Pain. *Current opinion in urology*. 2013;23(6):554-559.

31,41,51-54

Figure and Table Captions:

Table 2 Legend:

Author Manuscript

Abbreviation	Described
FDR	First-Degree Relatives
HC	Healthy Control
*	Outcome data reported on IC/BPS cohort only
NR	Not reported
W	White
Hisp	Hispanic
Nat-Am	Native American
Af-Am	African-American
RCT	Randomized Controlled Trial
MBSR	Mindfulness-Based Stress Reduction
TAU	Treatment-as-usual
UD	Urologic Disorders
AC	Acute Cystitis
RC	Radiation Cystitis
SR-IC/BPS	Self-report suggestive of IC/BPS
DMSO, BCG, PPS, CyA	Dimethyl Sulfoxide, Bacille Calmette-Guerin, Cyclosporine A, Pentosan Polysulfate Sodium

Author Manuscript

---

Table 3 Legend:

Abbreviation	Described
--------------	-----------

CES-D	Center for Epidemiological Studies of Depression
BDI-II	Beck Depression Inventory
HADS-A/D	Hospital Anxiety and Depression Scale
PSS	Perceived Stress Scale
CSQ	Coping Strategies Questionnaire
PCS	Pain Catastrophizing Scale
PCS	Physical Composite Scale
MCS	Mental Composite Scale
FSFI	Female Sexual Functioning Index

Table 4 Legend

<b>Abbreviation</b>	<b>Described</b>
CES-D	Center for Epidemiological Studies of Depression
STAI	State Trait Anxiety Inventory
STAXI	State Trait Anger Expression Inventory
HADS	Perceived Stress Scale
PANAS	Positive and Negative Affect Scale
BPCQ	Beliefs in Pain Control Questionnaire
CSQ	Coping Strategies Questionnaire
SEQ	Self-Efficacy Questionnaire
PCS	Pain Catastrophizing Scale
DAS	Dyadic Adjustment Scale
WHYMPI	West Haven Yale Multidimensional Pain Inventory



Table 1: Search Phrases by Information Source

Information Source	Search Phrase
PubMed, MEDLINE, Embase, CINAHL	("Cystitis, Interstitial" OR interstitial cystitis OR bladder pain syndrome OR bladder pain mapping network OR chronic prostatitis with chronic pelvic pain syndrome OR chronic pelvic pain syndrome) AND ("Anxiety" OR anxiety OR "Anxiety Disorder" OR "Depressive Disorder" OR depression OR "Sleep Initiation and Maintenance Disorders" OR insomnia OR "Quality of Life" OR "Post-Traumatic Stress Disorders, Post-Traumatic" OR quality of life OR post-traumatic stress disorders OR "Health Promotion" OR "Psychology" OR psychology OR health promotion OR psychology) AND (Clinical Trial OR Comparative Study OR Evaluation Studies OR Meta-Analysis OR Observational Study OR systematic)
Google Scholar (title search only)	NOT (drugs OR medications OR prescriptions OR pharmaceuticals) Search #1: Interstitial cystitis depression OR anxiety OR trauma OR "post traumatic stress disorder"  Search #2: bladder pain syndrome OR depression OR anxiety OR "post traumatic stress disorder"

Author	Sample N	Female	Male	Race	Study Type	Intervention	Relevant Outcomes
Carrico et al. (2008)	30 IC/BPS	100	0	100% W	RCT - Pilot	Guided Imagery (N= 15) vs. Resting (N = 15)	Overall improvement (GRA), IC/Efficacy (IC), Symptoms, Efficacy (IC)
Chiu et al. (2017)	97 IC/BPS, 43 AC	100	0	NR	Observational Cohort	N/A	Trauma pre (BBTS)*, Depression (II), Anxiety, Dissociation

Chuang et al. (2015)	185 IC/BPS, 370 HC	73	27	NR (Tiawanese sample)	Retrospective Cohort	N/A	Depression, Anxiety, Ins
Chung et al. (2014)	396 IC/BPS, 1980 HC	100	0	NR (Tiawanese sample)	Retrospective Cohort	N/A	Anxiety Dis Diagnosis
Clemens et al. (2008)	111 IC/BPS, 174 CP/CPPS, 247 HC	39	61	83% W, 14% non-white	Case-Control	N/A	Depression (9), Anxiety, Health Diag
El Khoudray et al. (2009)	41 IC/BPS	100	0	70.7% W, 29.3% non-white	Observational Cohort	N/A	QOL (SF-36), IC/BPS Syr
Fazio et al. (2014)	60 IC/BPS	94	6	94.1% W	Observational Cohort	N/A	Personality Assessment (MMPI-II)
Goldstein et al. (2008)	141 IC/BPS	100	0	NR	Observational Cohort	N/A	Depression (II), Abuse Prevalence
Kanter et al. (2016)	20 IC/BPS	100	0	70% W, 10% Nat-Am, 5% Asian, 15% Other	RCT	MBSR (N = 8) vs. TAU (N = 11)	Overall Improvement (SF-12), IC symptoms, Functioning
Kim & Heitkemper (2009)	130 IC/BPS, 168 HC	100	0	NR (Korean sample)	Observational Cohort	N/A	QOL (HRQL), Depression (KGDS)
Konkle et al (2012)	3674 IC/BPS	100	0	74.7% W, 9.9% Af-Am., 10.8% Hisp., 4.7% Other	Observational Cohort	N/A	QOL (SF-36), Prevalence, Panic Attac
Lai et al. (2015)	233 IC/BPS,	55	45	89% W, 11% non-	Observational Cohort	N/A	QOL (SF-12), Anger (PRC

	191 CP/PPS (UCPPS)*			white				Stress (PSS), Coping (CS), Depression (HADS)
Lee, Lin, et al (2014)	319 IC/BPS	86	14	NR (Tiawanese sample)	Observational Cohort	N/A		QOL
Lee, Wu et al (2014)	65 IC/BPS	NR	NR	NR	RCT	Online Health Education (N = 40) vs. TAU (N = 40)		QOL (SF-36)
Michael et al (2000)	99 IC/BPS, 98925 HC	100	0	NR	Case-Control	N/A		QOL (SF-36)
Naiboff et al (2015)	233 IC/BPS, 191 CP/PPS (UCPPS)*, 417 HC	55	45	89% W, 11% non-white	Case-Control	N/A		QOL (SF-36), Depression (HADS), Trauma Prevalence, Stress (PSS)
Nickel et al. (2008); Nickel et al. (2009)	128 IC/BPS	91	9	NR	Retrospective Analysis of RCT	PPS		QOL (SF-12), Insomnia (MOS-Sleep/Partia), Sexual Function (MOS-SexF)
Nickel et al. (2007)	217 IC/BPS	100	0	86% W, 7.4% Af-Am, 6.6% Other	Retrospective Analysis of RCT	BCG		QOL (SF-36), Sexual Function (SexFN)
Nickel et al (2011)	207 IC/BPS, 117 HC	100	0	NR	Case-Control	N/A		Trauma Prevalence (CTES), Depression (HADS), Anxiety

							Catastrophizing (PCS), Sex functioning, Social Support (MSPSS), C (SF-12)
Novi et al (2005)	46 IC/BPS, 46 HC	100	0	82.6% W, 15.2% Af-Am, 2.2% Hisp	Case-Control	N/A	Depression (9)
Peters et al (2007)	215 IC/BPS, 121 SR-IC/BPS, 464 HC	100	0	97% W, 1% Af-Am, 1% Hisp, 0.5% Asian	Case-Control	N/A	Trauma Prevalence
Rabin et al (2001)	74 IC/BPS	100	0	92.1% W, 3.9% Af-Am, 1.3% Asian, 1.3% Hisp, 1.3% Nat-Am	Observational Cohort	N/A	Depression (D), Self-efficacy (IC-SES)
Rapariz-Gonzalez et al (2014)	426 IC/BPS, 104 RC	91	9	NR	Case-Control	N/A	QOL (KHQ), Esteem (RS), Anxiety (GA)
Rothrock et al (2003); Rothrock et al (2002)	64 IC/BPS; 65 IC/BPS vs. 40 HC	100	0	89.1% white, 4.7% Nat-Am, 1.6% Asian, 3.1% 'other'	Observational Cohort	N/A	QOL (SF-36), Depression (HRSD), Coping Strategies ( )
Sairanen et al (2009)	151 IC/BPS	93	7	NR	Retrospective Analysis of RCT	DMSO vs. BCG (n = 87) and PPS vs. CyA (64)	QOL (HRQ)
Seth & Teichman (2008)	119 IC/BPS	100	0	NR	Retrospective Case-Control	N/A	Abuse Prevention, Sexual Function (FSFI)

Tripp et al (2009)	115 IC/BPS	100	0	94.8% White, 1.7% Af-Am, 1.7% Asian, 1.7% Hisp	Observational Cohort	N/A	QOL (SF-12), Depression (CESD), Catastrophizing (CSQ), Sex Functioning
Tripp et al (2016)	190 IC/BPS, 117 HC	100	0	90% W	Case-Control	N/A	Suicidality (9/single item), Depression (CESD), Catastrophizing (PCS)
Tripp et al (2012)	193 IC/BPS, 115 HC	100	0	89% W	Case-Control	N/A	QOL (SF-12), Depression (CESD), Catastrophizing (PCS)
Watkins et al. (2011)	1469 IC/BPS	100	0	80.1% W, 7.7% Af-Am, 7.4% Hisp	Observational Cohort	N/A	Depression (8), Anxiety (screen), QOL (36)
Weissman et al. (2004)	67 IC/BPS, 79 UD, 815 FDR	84	16	88.1% W	Case-Control	N/A	Anxiety Disorder Diagnosis (LA)
Zaslau et al (2008)	554 IC/BPS, 131 HC	100	0	NR	Case-Control	N/A	Sexual Functioning (FSFI)

Table 3: Pooled Statistics of Psychosocial Variables with Outpatient Comparison

Measure	Total N	Mean (SD)	Clinical Cutoffs & Interpretation
<b>Depression</b>			
CES-D	564	19.89 (13.12)	>16.0 cutoff for clinical depression <sup>37</sup> , >19 for clinical depression with chronic pain <sup>38</sup>
BDI-II	234	14.28 (8.51)	>14 mild depression, >20 moderate, >29 severe depression
HADS-D	465	5.65 (4.40)	>8 detects major depression <sup>53</sup>
<b>Anxiety, Stress, and Coping</b>			
HADS-A	465	8.15 (4.85)	>8 indicates 78% chance of having generalized anxiety disorder
PSS	659	18.61 (8.61)	>16 high health concern, >20 considered very high health concern, >25 need of intervention <sup>54</sup>
CSQ - CAT	466	14.15 (8.60)	>20 indicates high catastrophizing where patients are at greater risk for worse health outcomes <sup>55</sup>
PCS - Catastrophizing	503	22.07 (12.45)	Mean score is 20, >30 indicates clinically significant level of catastrophizing <sup>56</sup>
<b>Quality of Life</b>			
PCS (SF-12 and SF-36)	2912	42.37 (6.67)	< 47 below average physical health for U.S. population <sup>57</sup>
MCS (SF-12 and SF-36)	2912	40.80 (6.25)	<= 45 likely depression, <= 50 likely anxiety disorder, <36 likely severe psychological impairment <sup>58</sup>
FSFI	926	16.37 (8.12)	<= 26 at risk of sexual dysfunction needing further evaluation

Table 4: Recommended Psychosocial Assessment Instruments for pain in urologic disease


Domain	Purpose	Instrument	Included in meta-analysis
Affective Vulnerability	Depressed Mood	CES-D	Yes
	Anxious Mood	STAI	No
	Anger	STAXI	No
	Combination: depression/anxiety	HADS	Yes
	Combination: negative/positive affect	PANAS	No
Beliefs and Attitudes	Locus of Pain Control	BPCQ	No
	Coping Strategies	CSQ	Yes
	Self-efficacy	SEQ	No
	Catastrophizing	PCS	Yes
Environmental/social	Marital satisfaction	DAS	No
	Combination: work, family, social	WHYMPI	No

Note: Table adapted from "The importance of psychological assessment in chronic pain," by D. Williams, 2013, *Current Opinion in Urology* 23 (6),554-560. p556<sup>60</sup>

Author Manuscript



**Figure 1: Flow Diagram per PRISMA (2009)**



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement*. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).